Parasite | Eso | Sto | Cancer | ESD
[°Ç°°ËÁø ³»½Ã°æ Random Cases]
1. °ËÁø¿¡¼ ¹ß°ßµÈ º¸¸¸ 4Çü ÁøÇ༺ À§¾Ï
À§¾Ï ȯÀÚ°¡ Áõ»ó¾øÀÌ °Ç°ÇÏ°Ô Áö³»´Ù°¡ °Ç°°ËÁø ³»½Ã°æ ÈĺÎÅÍ Áõ»óÀÌ ¹ß»ýÇÒ ¼ö ÀÖÀ»±î¿ä? °Ç°°ËÁø ÀüÈÄ¿¡´Â ÀÚ½ÅÀÇ ¸ö, ÀÚ½ÅÀÇ Áõ»ó¿¡ ´ëÇÑ °ü½ÉÀÌ Ä¿Áö¹Ç·Î °ú°Å¿¡ ´À³¢Áö ¸øÇß´ø ½ÅüÀÇ ÀÌ»óÀ» ´À³¢´Â °æ¿ì°¡ ÀÖ´Â °Í °°½À´Ï´Ù.
¸î °³¿ù Àü ¿ÜºÎ¿¡¼ °Ç°°ËÁø ³»½Ã°æÀ» ¹Þ¾Ò´ø ȯÀÚ°¡ ÀǷڵǾú½À´Ï´Ù. ¾ÈŸ±õ°Ôµµ ´ç½Ã ³»½Ã°æ¿¡¼ 'º¸¸¸ 4Çü ÁøÇ༺ À§¾Ï'ÀÌ Áø´ÜµÇÁö ¸øÇÑ °Í °°½À´Ï´Ù. À§Ã¼ºÎÀÇ º´¼Ò´Â ¹Ì¾àÇÏ°í ÁÖ·Î fundus¿¡ À§Ä¡ÇÑ º¸¸¸ 4Çü ÁøÇ༺ À§¾ÏÀº ¸Å¿ì Áø´ÜÇϱ⠾î·Á¿î º´ÀÔ´Ï´Ù. ȯÀÚ´Â °Ç°°ËÁø ÁøÁ¤³»½Ã°æÀ» ¹ÞÀº ÈĺÎÅÍ ¼ÒȺҷ®, ¿¬ÇÏÀå¾Ö µîÀÌ ¹ß»ýÇÏ¿´´Ù°í ¸»ÇÏ¿´½À´Ï´Ù.
³»½Ã°æ Àç°ËÀ» ÇÏ¿´°í fundus Á¶Á÷°Ë»ç¿¡¼ poorly differentiated adenocarcinoma°¡ ³ª¿Ô½À´Ï´Ù. ¿ª½Ã º¸¸¸ 4Çü ÁøÇ༺ À§¾ÏÀ̾ú½À´Ï´Ù. °Ç°°ËÁø ³»½Ã°æ¿¡¼ °¡Àå µÎ·Á¿î ÀÏÀÌ º¸¸¸ 4Çü ÁøÇ༺ À§¾ÏÀ» ³õÄ¡´Â °ÍÀÔ´Ï´Ù. ¿ÃÇØ·Î ³»½Ã°æÀ» ¹è¿î Áö 20³âÀÔ´Ï´Ù. ¾ÆÁ÷ º¸¸¸ 4Çü ÁøÇ༺ À§¾ÏÀº ¾î·Æ½À´Ï´Ù. ¿ÀÈ÷·Á óÀ½º¸´Ù ´õ ¾î·Á¿öÁö´Â °Í °°½À´Ï´Ù. ¾Æ¸¶ ¿µ¿øÈ÷ ¾î·Á¿ï °Í °°½À´Ï´Ù.
© 2014.10.13. ÀÌÁØÇà
2. °ËÁø¿¡¼ ¹ß°ßµÈ À§¾Ï °£ÀüÀÌ
¹«Áõ»óÀε¥ ù Áø´ÜºÎÅÍ °£À¸·Î ÀüÀÌµÈ À§¾ÏÀÌ ÀÖ½À´Ï´Ù. ¾ÈŸ±î¿î ÀÏÀÔ´Ï´Ù.
3. °ËÁø¿¡¼ ¹ß°ßµÈ À§¾ÏÀÇ understaging
°ËÁø ³»½Ã°æ ÈÄ 'Á¶±â À§¾Ï'À¸·Î ÀÇ·ÚµÈ È¯ÀÚ¿´½À´Ï´Ù. »çÁøÀ» °ËÅäÇÏ¿´°í... ÁøÇ༺ À§¾ÏÀÌ Æ²¸²¾ø¾ú½À´Ï´Ù. ÀÌÀ¯´Â ¾Ë ¼ö ¾øÀ¸³ª ºñ½ÁÇÑ °æ¿ì°¡ ÀûÁö ¾Ê¾Ò½À´Ï´Ù. ¹«Áõ»óÀÌ°í °ËÁø ³»½Ã°æ¿¡¼ ¾ÏÀÌ ¹ß°ßµÇ¸é ¾Æ¹«·¡µµ ȯÀÚ¿¡°Ô "ÁøÇ༺ À§¾ÏÀÔ´Ï´Ù"¶ó°í ¸»¾¸µå¸®´Â °ÍÀÌ ºÒÆíÇϼ̴ø °Í °°½À´Ï´Ù. ±×·¡µµ Àú´Â Á¶±âÀ§¾Ï °°À¸¸é "Á¶±âÀ§¾Ï °°½À´Ï´Ù"°í ¼³¸íÇÏ°í ÁøÇ༺ À§¾Ï °°À¸¸é "ÁøÇ༺ À§¾Ï °°½À´Ï´Ù"¶ó°í ¼³¸íÇÏ´Â °ÍÀÌ ´õ ÁÁ´Ù°í »ý°¢ÇÕ´Ï´Ù. ÀÖ´Â ±×´ë·Î °¡°¨¾øÀÌ.
ÃÖÁ¾ º´¸®°á°úÀÔ´Ï´Ù.
Advanced gastric carcinoma
1. Location : lower third, Center at angle and lesser curvature
2. Gross type : Borrmann type 3
3. Histologic type : tubular adenocarcinoma, moderately differentiated
4. Histologic type by Lauren : intestinal
5. Size : 4.5x4 cm
6. Depth of invasion : invades serosa (pT4a)
7. Resection margin: free from carcinoma, safety margin: proximal 3 cm, distal 5 cm
8. Lymph node metastasis : metastasis to 3 out of 32 regional lymph nodes (pN2), (perinodal extension: present) (3/32: "1", 0/3; "3", 2/9; "4", 0/8; "5", 0/0; "6", 0/3; "7", 1/1; "9", 0/1; "8a", 0/3; "11p", 0/1; "12a", 0/3; "4sb", 0/0)
9. Lymphatic invasion : present
10. Venous invasion : not identified
11. Perineural invasion : present
12. Peritoneal cytology : negative
13. AJCC stage by 8th edition: pT4a N2
4. °ËÁø³»½Ã°æ¿¡¼ ¹ß°ßµÇ´Â ¿ø¹ß¼º À§¸²ÇÁÁ¾
¼¿ï´ëÇб³ °³²¼¾ÅÍ¿¡¼ °ËÁø³»½Ã°æ¿¡¼ ¹ß°ßµÈ ¿ø¹ß¼º À§¸²ÇÁÁ¾¿¡ ´ëÇÑ ³í¹®À» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù (Yang HJ. JGH 2016 - Epub).
Results: Of the 105,194 recipients of screening upper endoscopy, 52 (0.049%) were found to have PGL. The median age was 54.2 years (range 23-79), and 65.4% were female. The proportion of PGL to gastric malignancy was 12.1% (52/429) overall, but >30% (25/73) in middle-aged (40-59) females. PGLs in the screening group were more likely to be mucosa-associated lymphoid tissue (MALT) lymphoma (98.1% vs. 60.0%, P < 0.001) and treated with H. pylori eradication alone (90.0% vs. 48.1%, P < 0.001) than those in the outpatient group.
10¸¸ 5õ¿©¸íÀÇ °ËÁø ³»½Ã°æ Áß 429¸í(0.41%)¿¡¼ À§¾ÏÀÌ ¹ß°ßµÇ¾ú½À´Ï´Ù. 250¸í °ËÁø³»½Ã°æ¿¡¼ ÇÑ ¸íÀÇ À§¾ÏÀÌ ¹ß°ßµÈ ¼ÀÀÌ´Ï ¿ì¸®³ª¶ó ´ëÇüº´¿øÀÇ Æò±ÕÀûÀÎ ¼öÄ¡¿´½À´Ï´Ù. ±× Áß 12.1%(52/429)°¡ À§¸²ÇÁÁ¾À̾úÀ¸¸ç DLBCL (diffuse large B cell lymphoma) ÇÑ ¸í »©°í ¸ðµÎ Àúµµ MALT ¸²ÇÁÁ¾À̾ú½À´Ï´Ù. Àú´Â ¹«Áõ»ó gastric DLBCL¸¦ ¿©·¯¸í Áø·áÇÑ ¹Ù Àִµ¥ ´ëºÎºÐ ¾îµð¼±°¡ °ËÁø ³»½Ã°æ ÈÄ ÀÇ·ÚµÈ È¯ÀÚµéÀ̾ú½À´Ï´Ù. ±×·¡¼ 52¸í Áß ÇÑ ¸íÀ̶ó´Â ¼öÄ¡°¡ Á¶±Ý ³·°Ô ´À²¸Á³½À´Ï´Ù.
¾Æ·¡´Â ³í¹®¿¡¼ Á¦½ÃµÈ progression free survivalÀÔ´Ï´Ù. ºñ·Ï p value 0.399·Î Åë°èÀû Â÷ÀÌ°¡ ¾ø¾úÁö¸¸ °ÇÁø¹ß°ß ¸²ÇÁÁ¾¿¡ ºñÇÏ¿© ¿Ü·¡ ȯÀÚ Àúµµ ¸²ÇÁÁ¾ÀÇ progression free survivalÀÌ ´õ ³ªºüº¸Àδٴ Á¡ÀÌ Æ¯ÀÌÇß½À´Ï´Ù. ¿Ü·¡ ȯÀÚ Àúµµ ¸²ÇÁÁ¾ÀÇ »ó´ç¼ö°¡ Ÿ º´¿ø °ÇÁø¹ß°ß ¸²ÇÁÁ¾ÀÏ °ÍÀε¥ ¸»ÀÔ´Ï´Ù.
¼¿ï´ë °ËÁøÀÇ ³í¹®À» º¸´Ï ¹®µç ¿À·¡µÈ Áõ·Ê Çϳª°¡ »ý°¢³³´Ï´Ù. 2008³â 6¿ù 2ÀÏ '¿À´ÃÀÇ Áõ·Ê'¿´½À´Ï´Ù. °ËÁø ³»½Ã°æ¿¡¼ DLBCLÀÌ ¹ß°ßµÇ¾î Ç×¾ÏÄ¡·á¸¦ Çߴµ¥ ±×¸¸ õ°øÀÌ ¹ß»ýÇÑ °æ¿ì¿´½À´Ï´Ù. ȯÀڴ óÀ½ºÎÅÍ Ãµ°ø¹ß»ý½Ã±îÁö ¹«Áõ»óÀ̾ú´Âµ¥ Á¶±Ý ¹Ì¾ÈÇß½À´Ï´Ù. °ËÁø ³»½Ã°æÀ» ÇÏ´Ùº¸¸é ÀÌó·³ ¹Ì¾ÈÇÑ °æ¿ì°¡ Á¾Á¾ ¹ß»ýÇÕ´Ï´Ù. ¾Ö½Ã´çÃÊ Áõ»óÀÌ ¾ø´ø »ç¶÷À̹ǷΠġ·á¸¦ Çؼ ´õ ÇູÇÏ°Ô ¸¸µé±â´Â ¹«Ã´ ¾î·Á¿î ÀÏÀÔ´Ï´Ù. ´ç½ÃÀÇ À̹ÌÁö¿Í ¼³¸íÀ» ¿Å±é´Ï´Ù.
Screening endoscopyÀÇ ¸ñÀûÀº ¼ö¼úÀ̳ª EMR/ESD·Î Ä¡·áÇÒ ¼ö ÀÖ´Â À§¼±¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â °ÍÀÔ´Ï´Ù. À§¸²ÇÁÁ¾À» Áø´ÜÇϱâ À§ÇÏ¿© screening endoscopy¸¦ ½ÃÇàÇÏ´Â °ÍÀº ¾Æ´Õ´Ï´Ù¸¸ °£È¤ MALToma³ª DLBCL µîÀÌ Áø´ÜµÇ±âµµ ÇÕ´Ï´Ù. ¹«Áõ»ó DLBCLÀ» ¾î¶»°Ô Ä¡·áÇÏ´Â °ÍÀÌ ÁÁÀºÁö¿¡ ´ëÇÑ consensus´Â ¾ø½À´Ï´Ù. ÇöÀç·Î¼´Â Áõ»óÀÌ ÀÖ¾î ½ÃÇàÇÑ °Ë»ç¿¡¼ ¹ß°ßµÇ´Â DLBCL¿¡ ÁØÇÏ¿© Ä¡·á¸¦ ÇÏ°í ÀÖ½À´Ï´Ù.
ÃÖ±Ù ¸î¸î ³í¹®¿¡¼ GI lymphomaÀÇ chemotherapy ÈÄ perforationÀÇ À§ÇèÀÌ °ú°Å¿¡ »ý°¢ÇÏ¿´´ø °Íº¸´Ù ³ôÁö ¾Ê´Ù´Â ÁÖÀåÀÌ ÀÖ¾ú½À´Ï´Ù. ±×·¯³ª º» Áõ·Êó·³ ¾ÆÁ÷µµ °£È¤ chemotherapy ÈÄ perforationÀÌ ¹ß»ýÇϱ⵵ ÇÕ´Ï´Ù. Ä¡·á¸¦ ½ÃÀÛÇϱâ Àü¿¡ ¹Ýµå½Ã ȯÀÚ¿¡ ÀÌ·¯ÇÑ À§ÇèÀ» ¾Ë¸®´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù.
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.